cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immunogen Inc
14 own
29 watching
Current Price
$4.66
$-0.26
(-5.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,028.7M
52-Week High
52-Week High
6.63
52-Week Low
52-Week Low
3.095
Average Volume
Average Volume
1.97M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,028.7M
icon52-Week High6.63
icon52-Week Low3.095
iconAverage Volume1.97M
iconDividend Yield--
iconP/E Ratio--
What does the Immunogen Inc do?
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Immunogen Inc make?
News & Events about Immunogen Inc.
Zolmax
9days ago
ImmunoGen (NASDAQ:IMGN Get Rating) had its price target hoisted by JPMorgan Chase & Co. from $8.00 to $9.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has a neutral rating on the biotechnology companys stock. Several other analysts have also commented on ...
Zolmax
9days ago
ImmunoGen (NASDAQ:IMGN Get Rating) had its price target hoisted by JPMorgan Chase & Co. from $8.00 to $9.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has a neutral rating on the biotechnology companys stock. Several other analysts have also commented on ...
Business Wire
1month ago
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (pivekimab) in combination...
Business Wire
1month ago
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine (pivekimab) in...
PR Newswire
2 months ago
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope PR Newswire PALM BEACH, Fla., Dec. 1, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The...
Frequently Asked Questions
Frequently Asked Questions
What is Immunogen Inc share price today?
plus_minus_icon
Can Indians buy Immunogen Inc shares?
plus_minus_icon
How can I buy Immunogen Inc shares from India?
plus_minus_icon
Can Fractional shares of Immunogen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Immunogen Inc stocks?
plus_minus_icon
What is today’s traded volume of Immunogen Inc?
plus_minus_icon
What is today’s market capitalisation of Immunogen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Immunogen Inc?
plus_minus_icon
What percentage is Immunogen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Immunogen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.66
$-0.26
(-5.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.66
$-0.07 (-4.05 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$8.55
$0.02 (0.23 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$116.10
$-1.64 (-1.39 %)
TG Therapeutics Inc
TG Therapeutics Inc
$17.36
$-0.61 (-3.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.66
$-0.07 (-4.05 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$8.55
$0.02 (0.23 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$116.10
$-1.64 (-1.39 %)
TG Therapeutics Inc
TG Therapeutics Inc
$17.36
$-0.61 (-3.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00